Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients

- New labeling approval for Abbott's XIENCE ™ stent builds on a legacy of safety and allows for one-month (as short as 28 days) dual anti-platelet therapy (DAPT) for patients at high bleeding risk (HBR)
Source: Abbott.com - Category: Pharmaceuticals Source Type: news